AzTrials
AzTrials

MalariaPhase 1NCT02132299

Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

A Phase 1 study testing PfSPZ Vaccine and PfSPZ Challenge in people with Malaria and Plasmodium Falciparum Malaria, run by Sanaria Inc. at 1 site in Tanzania.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P. Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
Conditions the study is for
Malaria, Plasmodium Falciparum Malaria
What is being tested?
PfSPZ Vaccine and PfSPZ Challenge
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
67 participants
Where
1 siteTanzania
Study dates
Apr 2014to Aug 2015
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy male aged between 18 - 35 years.
  • Good health status based on history and clinical examination.
  • Long term or permanent resident in or near Dar-es-Salaam.
  • Able and willing to complete the study visit schedule over the one year follow up period, including the hospitalizations required for protocol compliance.
  • Able and willing to complete the informed consent process conducted in English.
  • Demonstrate understanding of the study and procedures by answering 20 questions from the Protocol \& Study Procedures Understanding Checklist correctly with a maximum of two attempts.
Show all 14Show fewer
  • Agrees to inform study doctor of medical conditions and contraindications for participation in the study.
  • Agrees to provide contact information to the study team for a household member who will serve as an emergency contact during trial participation.
  • Willing to be attended by a study doctor and take medications, which may be prescribed by a study doctor, during study participation.
  • Reachable (24/7) by mobile phone during the whole study period.
  • Agrees not to participate in another study during the study period.
  • Agrees not to donate blood during the study period.
  • Willing to undergo HIV, hepatitis B and hepatitis C testing.
  • Willing to undergo controlled human malaria infection (CHMI).

Who cannot join

  • History of malaria in the past 5 years.
  • Positive for malaria by thick blood smear at screening.
  • Plans to travel outside the Dar-es-Salaam or Coast Region in first 12 months of the study.
  • Previous receipt of an investigational malaria vaccine.
  • Antibodies to parasites or selected parasite protein(s) above acceptable cut off established for the site
  • History of arrhythmias or prolonged QT-interval or other cardiac disease or clinically significant abnormalities in electrocardiogram (ECG) at screening.
Show all 22Show fewer
  • History or indication of a history of drug or alcohol abuse interfering with normal social function.
  • Use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months of study enrollment (inhaled and topical corticosteroids are allowed).
  • Ongoing condition that could interfere with the interpretation of the study results or compromise the health of the volunteer.
  • History of diabetes mellitus or cancer.
  • Body Mass Index (BMI) below 18 or above 30 kg/m2.
  • Any clinically significant deviation from the normal range in biochemistry or hematology blood tests or in urine analysis or electrolytes.
  • Positive HIV, Hepatitis B virus or Hepatitis C virus tests.
  • Participation in any other clinical study within 30 days prior to study enrollment.
  • Known hypersensitivity, allergy, or other contra-indications to Coartem® or Malarone® including treatment taken by the volunteer that interferes with Coartem® or Malarone®.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including asplenia.
  • Heterozygous or homozygous for sickle cell or homozygous for alpha thalassemia.
  • Glucose-6-phosphate dehydrogenase deficiency
  • Psychiatric condition that precludes compliance with the protocol; past or present psychoses; disorder requiring lithium; or within five years prior to enrollment, history of suicide plan or attempt.
  • Any medical, psychiatric, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent, increases the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
  • History of 3 or more other immunizations within the six months before administration of the first dose of vaccine.
  • Clinically active tuberculosis

Trial locations and contacts

1 site in 1 country.

Tanzania1 site

  • Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74

    Bagamoyo

Other trials in Tanzania

About this study

Official title: Phase 1, Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults

This trial will evaluate whether relatively non-immune populations in endemic countries can effectively generate significant cellular and humoral immune responses that confer protection against P. falciparum infection after inoculation of aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) Plasmodium falciparum sporozoites (PfSPZ Vaccine) administered intravenously (IV).

Read the detailed description

This is a single center, Phase 1, dose escalating, randomized, double blind, controlled trial. Seventy-three healthy male volunteers, aged 18 to 35 years will be recruited. The study will have 5 study groups that will include 49 volunteers who will be intravenously injected with PfSPZ Vaccine, 8 control volunteers who will receive normal saline and 16 additional control volunteers who will be recruited at the time of controlled human malaria infection (CHMI) at 3 and 24 weeks. The control volunteers will help better assess the occurrence of AEs compared to background disease patterns that occur in this tropical area, and the performance of the vaccine.

Being tested
PfSPZ Vaccine, Normal Saline (Placebo), PfSPZ Challenge
Keywords
Malaria, Plasmodium falciparum malaria, PfSPZ Vaccine, PfSPZ Challenge, Controlled human malaria infection (CHMI)
Medical subject headings
Malaria, Malaria, Falciparum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PfSPZ VaccineBiological

    Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)

  • Normal Saline (Placebo)Biological

  • PfSPZ ChallengeBiological

    Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI

Study groups in NCT02132299
Study groupRoleWhat they receive
Group 1ExperimentalThree volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
Receives: Biological: PfSPZ Vaccine
Group 2(A)ExperimentalGroup 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
Receives: Biological: PfSPZ Vaccine; Biological: PfSPZ Challenge
Group 2(B)Placebo comparatorGroup 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
Receives: Biological: Normal Saline (Placebo); Biological: PfSPZ Challenge
Group 3(A)ExperimentalGroup 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
Receives: Biological: PfSPZ Vaccine; Biological: PfSPZ Challenge
Group 3(B)Placebo comparatorGroup 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
Receives: Biological: Normal Saline (Placebo); Biological: PfSPZ Challenge
Group 4ExperimentalThe fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
Receives: Biological: PfSPZ Vaccine; Biological: PfSPZ Challenge
Group 5Placebo comparatorThe 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
Receives: Biological: PfSPZ Challenge

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety and tolerability endpoints

    • Solicited local (IV site) and systemic AEs (AEs) observed in the 7 days after each vaccination and each CHMI.
    • Unsolicited AEs observed after the first vaccination until day 28 after the last vaccination for volunteers who do not undergo CHMI#1 (e.g. Group 1, those who do not complete the CHMI portion in Groups 2 and 3, and volunteers in Group 4).
    • Unsolicited AEs observed after the first vaccination until day 28 after the CHMI#1 for volunteers who undergo CHMI#1 3 weeks after the last vaccination (e.g. Groups 2 and 3).
    • Unsolicited AEs observed from day CHMI#2 (which occurs 24 weeks after the last vaccination) until day 28 after CHMI#2 (e.g. Groups 2-5).

    Measured: Vaccination to CHMI (or 28 days after last vaccination); CHMI to 28 days after CHMI

  2. Protective Efficacy after CHMI with PfSPZ Challenge (NF54) - CHMI Endpoints

    Number of volunteers that remain parasite negative in each group through day 28 of follow up after CHMI with PfSPZ Challenge (NF54) IV inoculation.

    Three weeks after their last immunization, volunteers in Groups 2 and 3 will under go their first CHMI with 3.2 x 10^3 PfSPZ Challenge (NF54) administered IV. Twenty-four weeks after the last immunization, volunteers from Groups 2 and 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). Volunteers in Groups 4 and 5 will only participate in the second CHMI assessment.

    After CHMI, volunteers will be followed for evidence of infection with blood smears for 28 days.

    Measured: CHMI to 28 days after CHMI

Secondary outcomes (2)

  1. Immune Responses after PfSPZ Vaccine

    Cellular and humoral immune responses will be assessed in the vaccinated volunteers and controls (including central and effector memory responses and breadth and specificity of malaria antibodies).

    Measured: 16 months

  2. Protective effect of the high dose PfSPZ Vaccine regimen

    Number of volunteers negative in Group 3 and Group 4 compared to Group 2 through day 28 of follow up after homologous PfSPZ Challenge (NF54) IV inoculation.

    Measured: CHMI to day 28 after CHMI

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 May 2014 (estimated)
  2. Study startApr 2014
  3. Primary completionJul 2015
  4. Study completionAug 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
67 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02132299
Sponsor's protocol ID
BSPZV1
Status last verified
Apr 2016
First submitted
29 Apr 2014
Last updated
27 Apr 2016
Results posted
No
Data monitoring committee
Yes

Publications

  • Jongo SA, Shekalaghe SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, Rutishauser T, Rothen J, Tumbo A, Mkindi C, Mpina M, Mtoro AT, Ishizuka AS, Kassim KR, Milando FA, Qassim M, Juma OA, Mwakasungula S, Simon B, James ER, Abebe Y, Kc N, Chakravarty S, Saverino E, Bakari BM, Billingsley PF, Seder RA, Daubenberger C, Sim BKL, Richie TL, Tanner M, Abdulla S, Hoffman SL. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am J Trop Med Hyg. 2018 Aug;99(2):338-349. doi: 10.4269/ajtmh.17-1014. Epub 2018 Jun 21.

    PubMed 29943719

  • Zenklusen I, Jongo S, Abdulla S, Ramadhani K, Lee Sim BK, Cardamone H, Flannery EL, Nguyen T, Fishbaugher M, Steel RWJ, Betz W, Carmago N, Mikolajczak S, Kappe SHI, Hoffman SL, Sack BK, Daubenberger C. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies. J Infect Dis. 2018 Apr 23;217(10):1569-1578. doi: 10.1093/infdis/jiy080.

    PubMed 29438525

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing PfSPZ Vaccine and PfSPZ Challenge in people with Malaria and Plasmodium Falciparum Malaria, run by Sanaria Inc. at 1 site in Tanzania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Apr 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Tanzania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety and tolerability endpoints (time frame: Vaccination to CHMI (or 28 days after last vaccination); CHMI to 28 days after CHMI). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02132299, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2016.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in